About 7% of adults in the United States are diagnosed with dry eye disease (DED). In this article, Francis Mah, MD, an ophthalmologist with Scripps Clinic in La Jolla, California, discusses the role of inflammation in DED development, shares therapeutic approaches, and explains how to tailor treatment to specific patients’ needs.
Special Collections
Clinician POV
Thyroid eye disease is one of the most common causes of proptosis in adults. Prior to the approval of teprotumumab, antithyroid drugs and radioiodine therapies were traditionally seen as mainstays of therapy. David P. Sendrowski, OD, FAAO, a professor at the Marshall B. Ketchum University’s Southern California College of Optometry in Fullerton, delves into how the optometry profession is equipped to manage TED and ways in which teprotumumab has changed the treatment landscape for patients with TED.
